Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis US Commercial Headquarters & R&D in East Hanover, New by Year
US Commercial Headquarters & R&D in East Hanover, New Jersey (m²)
Novartis US Commercial Headquarters & R&D in East Hanover, New: 123,751 in FY2025, down 52.1% from a year earlier.
Latest, FY2025
123,751
Period ended Dec 31, 2025
Change on a year earlier
-52.1%
258,180 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| East Hanover, NJ, US | 123 751 | US organizational unit headquarters; research and development”
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Item 4.D.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | US Commercial Headquarters & R&D in East Hanover, New Jersey (m²) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 123,751 | -52.1% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 258,180 | -6.8% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2023 | Dec 31, 2023 | 277,015 | – | Novartis Form 20-F (0001370368-24-000004) ↗ |
Cite this data
StockData. (2026). Novartis US Commercial Headquarters & R&D in East Hanover, New, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/fac-easthanover-m2
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.